Eposis2000 IU

Eposis is an erythropoiesis-stimulating agent (ESA), a recombinant form of human Eposis that stimulates red blood cell production. It is FDA-approved and guideline-supported for the following established indications:

• Anemia of chronic kidney disease (CKD): In patients on dialysis and patients not on dialysis, to reduce the need for red blood cell (RBC) transfusions.
• Chemotherapy-induced anemia: In patients with non-myeloid malignancies whose anemia is due to the effect of concomitant myelosuppressive chemotherapy, when at least two additional months of chemotherapy are planned. Not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
• Anemia due to zidovudine therapy in HIV-infected patients with endogenous serum Eposis levels ≤500 mUnits/mL and receiving zidovudine doses ≤4200 mg/week.
• Reduction of allogeneic RBC transfusion in patients undergoing elective, noncardiac, nonvascular surgery who have a hemoglobin between 10 and 13 g/dL and are at high risk for perioperative blood loss.

Important limitations: Eposis is not indicated and is not FDA-approved for improvement of quality of life, fatigue, or general well-being; for cancer patients receiving hormonal agents, biologic products, or radiotherapy only (without concomitant myelosuppressive chemotherapy); for patients who are able to donate autologous blood; or for use in patients undergoing cardiac or vascular surgery. Therapy should target the lowest dose sufficient to reduce the need for RBC transfusion, not to normalize hemoglobin (see Precautions and Warnings for the boxed warning).

Each vial/pre-filled syringe contains Erythropoietin (recombinant human erythropoietin, epoetin alfa) as the active ingredient, supplied as a sterile solution for injection in strengths typically ranging from 1,000 IU to 10,000 IU per vial/syringe. Formulations may contain excipients such as human albumin or polysorbate, sodium citrate/citric acid buffer, sodium chloride, and (in multi-dose vials) benzyl alcohol as a preservative. Exact composition varies by brand and formulation strength; refer to the specific product label.

Eposis is a glycoprotein hormone produced by recombinant DNA technology that is structurally and biologically similar to endogenous human Eposis, the hormone normally produced by the kidneys that stimulates the bone marrow to produce red blood cells. It is administered by intravenous (IV) or subcutaneous (SC) injection and is used to treat certain forms of anemia by stimulating erythropoiesis (red blood cell production) in the bone marrow.

Eposis carries an FDA boxed warning because erythropoiesis-stimulating agents, when used to target higher hemoglobin levels than recommended, increase the risk of serious cardiovascular events and, in cancer patients, may shorten survival or increase the risk of tumor progression/recurrence. Treatment must be individualized by a physician, with regular monitoring of hemoglobin and dose adjustment based on response.

Eposis belongs to the therapeutic class of Erythropoiesis-Stimulating Agents (ESAs), also referred to as anti-anemic recombinant human Eposiss.

Erythropoietin is a recombinant human erythropoietin that acts by binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow. This binding stimulates cell division and differentiation of these progenitor cells into mature red blood cells, increasing reticulocyte counts within approximately 10 days and hemoglobin/hematocrit levels within approximately 2-6 weeks.

Endogenous erythropoietin is normally produced primarily by the kidneys in response to hypoxia. In patients with chronic kidney disease, endogenous erythropoietin production is impaired, contributing to anemia; Erythropoietin replaces this deficient hormonal signal. In chemotherapy-induced anemia, Erythropoietin similarly stimulates red cell production to offset bone marrow suppression caused by cytotoxic drugs.

Adequate iron stores are required for an effective erythropoietic response to Erythropoietin; iron deficiency should be corrected before and during treatment, as it is the most common cause of an inadequate response.

Eposis is administered by intravenous (IV) or subcutaneous (SC) injection only; it is not given orally. It is typically administered or supervised by a healthcare professional; in some cases, patients or caregivers may be trained to self-inject subcutaneously, but the dose and schedule must always be determined and adjusted by the physician based on hemoglobin monitoring, never self-adjusted by the patient. Do not shake the vial or syringe. Do not mix with other drug solutions. Discard any unused portion of single-dose vials; multi-dose vials should be used according to labeled storage limits after first entry.

No specific clinically significant pharmacokinetic drug-drug interactions are well established for Eposis. Clinically relevant considerations include:

• Iron supplementation: Concomitant iron therapy is often required to support and maintain the erythropoietic response, particularly if serum ferritin is low or transferrin saturation is reduced; inadequate iron stores blunt response to Eposis.
• Drugs affecting blood pressure: Because Eposis commonly causes or worsens hypertension, concurrent antihypertensive therapy may need adjustment; blood pressure must be controlled before and during treatment.
• Anticoagulants/antiplatelet agents: Given the increased risk of thromboembolic events with Eposis, caution and clinical judgment are needed when used concurrently with agents affecting clotting, particularly in the perioperative setting where thromboprophylaxis is recommended.

Common and serious adverse effects reported with Eposis include:

• Very common: Hypertension (including severe hypertension), arthralgia/myalgia, fever, headache, nausea and vomiting, injection site pain/reactions, dizziness, fatigue.
• Serious/important: Increased risk of death, myocardial infarction, stroke, and venous thromboembolism when hemoglobin is targeted above recommended levels (see Precautions and Warnings); pure red cell aplasia (rare, with prolonged use); seizures, particularly in CKD patients with rapid hematocrit rise; serious allergic reactions including anaphylaxis, angioedema, and bronchospasm; severe cutaneous reactions including Stevens-Johnson syndrome/toxic epidermal necrolysis (rare).
• Other reported effects: Cough, rash/urticaria, hyperkalemia, hyperglycemia, insomnia, depression, edema, and vascular access thrombosis in dialysis patients.

Pregnancy: Data on the use of Eposis in pregnant women are limited. Animal reproduction studies have shown adverse effects (embryo-fetal death, skeletal anomalies, growth reduction) at doses producing exposures well above the recommended human dose range. Eposis should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; a physician must be consulted before use. Multi-dose (benzyl alcohol-containing) formulations must not be used in pregnant women.

Lactation: There is limited information on the presence of Eposis in human milk; endogenous Eposis is naturally present in breast milk. Breastfeeding is generally not recommended for a period after use of benzyl alcohol-containing multi-dose formulations; single-dose, preservative-free formulations may be considered with caution and physician guidance, weighing the benefits of breastfeeding against any potential risk.

Boxed Warning

Eposis, like other erythropoiesis-stimulating agents, carries a boxed warning: in controlled clinical trials, targeting a hemoglobin level greater than 11 g/dL increased the risk of death, myocardial infarction, stroke, and venous thromboembolism in patients with chronic kidney disease. In patients with cancer, ESAs including Eposis increased the risk of death and of tumor progression or recurrence when used to target a hemoglobin of 12 g/dL or greater. To minimize these risks, use the lowest dose of Eposis sufficient to reduce the need for RBC transfusions, and use only if the benefit of decreasing transfusions outweighs these risks. Eposis is not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure.

Hypertension

Blood pressure commonly rises or worsens during Eposis therapy, sometimes leading to hypertensive encephalopathy or seizures. Blood pressure must be adequately controlled before starting Eposis and monitored closely throughout treatment.

Seizures

Eposis increases the risk of seizures, particularly in patients with CKD, especially during the first several months of therapy when hemoglobin/hematocrit is rising rapidly. Monitor closely for new-onset seizures or premonitory symptoms.

Pure Red Cell Aplasia (PRCA)

Rarely, prolonged use of Eposis can lead to the development of neutralizing antibodies to Eposis, causing PRCA — severe anemia with very low reticulocyte count. If a patient develops sudden loss of response with severe anemia, Eposis should be withheld and the patient evaluated for antibody-mediated PRCA; Eposis and other ESAs must not be restarted.

Serious Allergic Reactions and Skin Reactions

Anaphylaxis, angioedema, bronchospasm, skin rash, and urticaria have been reported. Severe cutaneous adverse reactions (Stevens-Johnson syndrome/toxic epidermal necrolysis) have rarely occurred. Discontinue Eposis immediately if a serious hypersensitivity or severe skin reaction occurs.

Thromboembolic Events

Eposis increases the risk of deep vein thrombosis and other thromboembolic events, particularly in the perioperative surgical setting; thromboprophylaxis is recommended when Eposis is used perioperatively.

Physician Supervision Required

Eposis must only be prescribed and dose-adjusted by a physician, with regular hemoglobin monitoring. It should never be self-initiated or self-adjusted by the patient.

Overdose of Eposis can cause an excessive, too-rapid rise in hemoglobin/hematocrit, which increases the risk of severe hypertension, hypertensive crisis, seizures, and serious cardiovascular events such as myocardial infarction, stroke, and thromboembolism. There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact a physician, hospital emergency department, or poison control center right away. Management is supportive and may include withholding Eposis, close monitoring of blood pressure and hemoglobin, and phlebotomy (as clinically indicated by the treating physician) if hemoglobin rises excessively. Do not attempt to manage a suspected overdose at home.

Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze; discard if the product has been frozen. Protect from light — keep in the outer carton until time of use. Do not shake vigorously, as this may denature the product and reduce effectiveness. Keep out of reach of children. Do not use after the expiry date printed on the pack.

Renal Impairment

Eposis is specifically indicated for anemia of chronic kidney disease, including patients on and not on dialysis; dosing is individualized based on hemoglobin response (see Dosage and Administration).

Hepatic Impairment

No well-established dose adjustment for hepatic impairment is defined in labeling; use with clinical caution and physician supervision.

Elderly

No overall differences in safety or effectiveness have been established between elderly and younger adult patients; use with the same monitoring precautions, considering the higher likelihood of cardiovascular comorbidity in this age group.

Pediatric Use

Eposis is approved for anemia of CKD in pediatric patients 1 month of age and older, and for chemotherapy-induced anemia in pediatric patients 5 years of age and older, at weight-based doses (see Dosage and Administration). Safety and effectiveness for other indications in children have not been established.

Duration of treatment with Eposis depends on the indication and is determined by the treating physician based on ongoing hemoglobin response. In CKD, treatment is typically long-term/chronic as long as anemia management is needed. In chemotherapy-induced anemia, treatment continues for the duration of myelosuppressive chemotherapy plus approximately 2 additional months, and should be discontinued following completion of a chemotherapy course. In the perioperative setting, treatment is given over a defined short course of up to about 3-4 weeks around the time of surgery. Treatment should not continue for longer than clinically necessary at the lowest effective dose.

Erythropoietin belongs to the drug class of Erythropoiesis-Stimulating Agents (ESAs), also known as recombinant human erythropoietins or hematopoietic growth factors acting on the erythroid lineage.

Erythropoietin binds to erythropoietin receptors on erythroid progenitor cells in the bone marrow, stimulating their proliferation and differentiation into mature red blood cells, thereby increasing red blood cell production (erythropoiesis) and raising hemoglobin/hematocrit levels over several weeks.

Eposis is approved for use in pediatric patients for select indications: anemia of chronic kidney disease in infants and children 1 month of age and older, and chemotherapy-induced anemia in children 5 years of age and older, using weight-based dosing under close physician supervision with regular hemoglobin monitoring. Safety and efficacy for other indications (e.g., HIV/zidovudine-associated anemia, perioperative use) have not been established in pediatric patients. Multi-dose, benzyl alcohol-containing formulations must not be used in neonates and infants due to risk of fatal toxicity; only single-dose, preservative-free formulations should be used in this age group.